Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection
22. Dezember 2015 aktualisiert von: Boehringer Ingelheim
Safety, Antiviral Effect and Pharmacokinetics of BI 207127 in Combination With BI 201335 and With or Without Ribavirin for 4, 16, 24, 28 or 40 Weeks in Patients With Chronic HCV Genotype 1 Infection (Randomized Phase Ib/II)
The substances BI 201335 and BI 207127 are being developed for the treatment of chronic hepatitis C virus infection. BI 201335 and BI 207127 work by preventing the virus from replicating.
The currently available medications pegylated interferon alfa and ribavirin for hepatitis C ca have considerable adverse events in patients and in many cases are not sufficiently effective. This is particularly the case in treatment of patients infected with genotype 1 of HCV.
A combination therapy of these new substances without pegylated interferon alfa may be associated with fewer adverse events that currently available (pegylated interferon-alfa-based) medication and may also provide a treatment option to the large number of patients with contraindications or intolerance to pegylated interferon alfa.
This clinical trial (1241.21) currently consists of 3 distinct studies: Part 1, Part 2 and Part 3.
Part 1 (SOUND-C1) is a 2 armed study as described in experimental arms 1 and 2 below (actual enrollment: 56 patients; randomized and treated: 32) Part 2 (SOUND-C2) is a 5 armed study as described in experimental arms 3 to 7 below (actual enrollment: 465; randomized and treated: 362) Part 3 (SOUND-C3) includes 3 arms as described in experimental arms 8 to 10 below (83 patients randomized and treated)
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
- Arzneimittel: BI 207127
- Arzneimittel: BI 201335
- Arzneimittel: BI 207127
- Arzneimittel: BI 201335
- Arzneimittel: Ribavirin
- Arzneimittel: Ribavirin
- Arzneimittel: BI 207127
- Arzneimittel: BI 207127
- Arzneimittel: BI 207127
- Arzneimittel: Ribavirin
- Arzneimittel: Ribavirin
- Arzneimittel: BI 207127
- Arzneimittel: BI 201335
- Arzneimittel: BI 201335
- Arzneimittel: Ribavirin
- Arzneimittel: BI 207127
- Arzneimittel: BI 207127
- Arzneimittel: BI 207127
- Arzneimittel: BI 207127
- Arzneimittel: BI 207217
Studientyp
Interventionell
Einschreibung (Tatsächlich)
488
Phase
- Phase 2
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
Victoria
-
Heidelberg, Victoria, Australien
- 1241.21.61002 Boehringer Ingelheim Investigational Site
-
Melbourne, Victoria, Australien
- 1241.21.61001 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Berlin, Deutschland
- 1241.21.49002 Boehringer Ingelheim Investigational Site
-
Berlin, Deutschland
- 1241.21.49003 Boehringer Ingelheim Investigational Site
-
Düsseldorf, Deutschland
- 1241.21.49007 Boehringer Ingelheim Investigational Site
-
Esslingen, Deutschland
- 1241.21.49005 Boehringer Ingelheim Investigational Site
-
Frankfurt am Main, Deutschland
- 1241.21.49001 Boehringer Ingelheim Investigational Site
-
Hamburg, Deutschland
- 1241.21.49006 Boehringer Ingelheim Investigational Site
-
Hannover, Deutschland
- 1241.21.49009 Boehringer Ingelheim Investigational Site
-
Leipzig, Deutschland
- 1241.21.49004 Boehringer Ingelheim Investigational Site
-
Mainz, Deutschland
- 1241.21.49008 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Clichy, Frankreich
- 1241.21.33005 Boehringer Ingelheim Investigational Site
-
Grenoble cédex 9, Frankreich
- 1241.21.33007 Boehringer Ingelheim Investigational Site
-
Lyon, Frankreich
- 1241.21.33003 Boehringer Ingelheim Investigational Site
-
Marseille, Frankreich
- 1241.21.33001 Boehringer Ingelheim Investigational Site
-
Montpellier, Frankreich
- 1241.21.33002 Boehringer Ingelheim Investigational Site
-
Paris, Frankreich
- 1241.21.33004 Boehringer Ingelheim Investigational Site
-
Paris, Frankreich
- 1241.21.33008 Boehringer Ingelheim Investigational Site
-
Vandoeuvre Cedex, Frankreich
- 1241.21.33006 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Auckland NZ, Neuseeland
- 1241.21.64001 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Aveiro, Portugal
- 1241.21.35103 Boehringer Ingelheim Investigational Site
-
Coimbra, Portugal
- 1241.21.35104 Boehringer Ingelheim Investigational Site
-
Lisboa, Portugal
- 1241.21.35101 Boehringer Ingelheim Investigational Site
-
Lisboa, Portugal
- 1241.21.35105 Boehringer Ingelheim Investigational Site
-
Porto, Portugal
- 1241.21.35102 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bucharest, Rumänien
- 1241.21.40001 Boehringer Ingelheim Investigational Site
-
Bucharest, Rumänien
- 1241.21.40002 Boehringer Ingelheim Investigational Site
-
Bucharest, Rumänien
- 1241.21.40003 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Basel, Schweiz
- 1241.21.41003 Boehringer Ingelheim Investigational Site
-
Bern, Schweiz
- 1241.21.41006 Boehringer Ingelheim Investigational Site
-
St. Gallen, Schweiz
- 1241.21.41001 Boehringer Ingelheim Investigational Site
-
Zürich, Schweiz
- 1241.21.41002 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Barcelona, Spanien
- 1241.21.34002 Boehringer Ingelheim Investigational Site
-
Barcelona, Spanien
- 1241.21.34005 Boehringer Ingelheim Investigational Site
-
Madrid, Spanien
- 1241.21.34003 Boehringer Ingelheim Investigational Site
-
Madrid, Spanien
- 1241.21.34004 Boehringer Ingelheim Investigational Site
-
Majadahonda-Madrid, Spanien
- 1241.21.34001 Boehringer Ingelheim Investigational Site
-
Valencia, Spanien
- 1241.21.34006 Boehringer Ingelheim Investigational Site
-
-
-
-
California
-
La Jolla, California, Vereinigte Staaten
- 1241.21.0003 Boehringer Ingelheim Investigational Site
-
San Diego, California, Vereinigte Staaten
- 1241.21.0006 Boehringer Ingelheim Investigational Site
-
San Francisco, California, Vereinigte Staaten
- 1241.21.0004 Boehringer Ingelheim Investigational Site
-
-
Florida
-
Palm Harbor, Florida, Vereinigte Staaten
- 1241.21.0011 Boehringer Ingelheim Investigational Site
-
-
Indiana
-
Valparaiso, Indiana, Vereinigte Staaten
- 1241.21.0013 Boehringer Ingelheim Investigational Site
-
-
Massachusetts
-
Springfield, Massachusetts, Vereinigte Staaten
- 1241.21.0008 Boehringer Ingelheim Investigational Site
-
-
North Carolina
-
Fayetteville, North Carolina, Vereinigte Staaten
- 1241.21.0019 Boehringer Ingelheim Investigational Site
-
-
Texas
-
Arlington, Texas, Vereinigte Staaten
- 1241.21.0012 Boehringer Ingelheim Investigational Site
-
Austin, Texas, Vereinigte Staaten
- 1241.21.0005 Boehringer Ingelheim Investigational Site
-
Dallas, Texas, Vereinigte Staaten
- 1241.21.0007 Boehringer Ingelheim Investigational Site
-
Houston, Texas, Vereinigte Staaten
- 1241.21.0010 Boehringer Ingelheim Investigational Site
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten
- 1241.21.0017 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Linz, Österreich
- 1241.21.43003 Boehringer Ingelheim Investigational Site
-
Wien, Österreich
- 1241.21.43001 Boehringer Ingelheim Investigational Site
-
Wien, Österreich
- 1241.21.43002 Boehringer Ingelheim Investigational Site
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre bis 75 Jahre (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion criteria:
- Chronic hepatitis C virus (HCV) infection of genotype (GT) 1
- Parts 1-3:Treatment naive to Interferon -alfa (IFN), Pegylated interferon -alfa (PegIFN), ribavirin (RBV), and any direct acting antiviral agent for chronic hepatitis C
- Part 4: Treatment experienced with confirmed prior virological failure to an approved dose of PegIFN/RBV (null-response)
- HCV RNA >=10,000 IU/mL at screening
- Liver biopsy within two years or fibroscan within six months prior to baseline
- Liver biopsy within two years or fibroscan within 6 months prior to screening
- Age 18-75 years
Exclusion criteria:
- Hepatitis C virus (HCV) infection of mixed genotype
- Evidence of liver disease due to causes other than chronic HCV infection
- Positive ELISA for human immunodeficiency virus (HIV)
- Hepatitis B virus (HBV) infection
- Decompensated liver disease or history of decompensated liver disease
- Active or suspected malignancy within the last 5 years
- Ongoing or historical photosensitivity or recurrent rash
- History of alcohol or drug abuse (except cannabis) within the past 12 months
- Body mass index (BMI)I <18 or > 35 kg/m2
- Usage of any investigational drugs within 30 days prior to enrolment, or 5 half-lives, whichever is longer; o the planned usage of an investigational drug during the course of the current study
- Known hypersensitivity to any ingredient of the study drugs
- A condition that is defined as one which in the opinion of the investigator may interfere with the patient's capability for participation in the trial or may influence the results of the trial
- Alpha fetoprotein >100ng/mL at screening; if >20ng/mL and <=100ng/mL, patients can be included if there is no evidence of liver cancer in an appropriate imaging study within 6 months prior to randomisation
- Total bilirubin > 2 mg/dL with ratio of direct/indirect > 1
- AST or ALT >5xULN
- INR prolonged to >1.7xULN
- Requirement for chronic systemic corticosteroids
- Received concomitant systemic antiviral, hematopoietic growth factor, or immunomodulatory treatment within 30 days prior to enrolment or 5 half-lives, whichever is longer
- Received silymarin or glycyrrhizin or Sho-saiko-to within 30 days prior to enrolment
- Contraindications pertaining to PegIFN or RBV
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: 2
4 weeks of high dose TID BI 207127 and QD BI 201335 in combination with RBV, Part 1
|
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
48 weeks, according to label
40 weeks, according to label
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, according to label
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
|
|
Experimental: 1
4 weeks of low dose three times per day (TID) BI 207127 and once daily (QD) BI 201335 in combination with RBV, Part 1
|
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
48 weeks, according to label
40 weeks, according to label
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, according to label
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
|
|
Experimental: 3
16 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 2
|
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
48 weeks, according to label
40 weeks, according to label
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, according to label
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
|
|
Experimental: 4
28 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 2
|
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
48 weeks, according to label
40 weeks, according to label
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, according to label
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
|
|
Experimental: 5
40 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 2
|
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
48 weeks, according to label
40 weeks, according to label
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, according to label
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
|
|
Experimental: 6
28 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 2
|
40 weeks, QD
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
48 weeks, according to label
40 weeks, according to label
28 weeks, QD
16 weeks, QD
24 weeks, according to label
28 weeks, high dose BID
|
|
Experimental: 7
28 weeks of TID BI 207127 and QD BI 201335 without RBV, Part 2
|
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
|
|
Experimental: 8
16 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 3
|
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
48 weeks, according to label
40 weeks, according to label
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, according to label
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
|
|
Experimental: 9
24 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 3
|
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
48 weeks, according to label
40 weeks, according to label
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, according to label
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
|
|
Experimental: 10
24 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 3
|
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
48 weeks, according to label
40 weeks, according to label
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, according to label
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
|
|
Experimental: 11
16 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 4
|
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
48 weeks, according to label
40 weeks, according to label
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, according to label
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
|
|
Experimental: 12
24 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 4
|
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
48 weeks, according to label
40 weeks, according to label
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, according to label
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Part 1: Rapid Virological Response (RVR)
Zeitfenster: 4 weeks
|
Part 1: Rapid virological response (RVR), defined as Hepatitis C Virus Ribonucleic acid (HCV RNA) <25IU/mL at Week 4 of treatment
|
4 weeks
|
|
Part 2: Sustained Virological Response (SVR)
Zeitfenster: From drug administration until 12 weeks after end of treatment, up to 52 weeks
|
Part 2: Sustained virological response (SVR), defined as HCV RNA <25 IU/mL and undetectable at 12 weeks after end of treatment
|
From drug administration until 12 weeks after end of treatment, up to 52 weeks
|
|
Part 3 and 4: Sustained Virological Response (SVR)
Zeitfenster: From drug administration until 12 weeks after end of treatment, up to 36 weeks
|
Part 3 and 4: Sustained virological response (SVR) defined as HCV RNA <25IU/mL and undetectable at 12 weeks after end of treatment
|
From drug administration until 12 weeks after end of treatment, up to 36 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Part 1: Time to Virological Response
Zeitfenster: From drug administration until end of drug administration, up to 4 weeks
|
Part 1: Time to virological response, defined as the timepoint of the first measurement of plasma HCV RNA level <25 IU/mL.
The percentage of participants who achieved virological response within each time period are displayed for this outcome measure.
|
From drug administration until end of drug administration, up to 4 weeks
|
|
Part 2: Time to Virological Response
Zeitfenster: From drug administration until end of drug administration, up to 40 weeks
|
Part 2: Time to virological response, defined as the timepoint of the first measurement of plasma HCV RNA level <25 IU/mL.
The percentage of participants who achieved virological response within each time period are displayed for this outcome measure.
|
From drug administration until end of drug administration, up to 40 weeks
|
|
Part 1 and 2: Plasma HCV RNA Level Not Detectable at Week 4
Zeitfenster: 4 weeks
|
Part 1 and 2: Plasma Hepatitis C Virus Ribonucleic acid (HCV RNA) level not detectable at Week 4
|
4 weeks
|
|
Part 2: Sustained Virological Response at 4 and 24 Weeks After End of Treatment
Zeitfenster: 4 weeks and 24 weeks after the end of treatment, up to 64 weeks
|
Part 2: Sustained virological response at 4 and 24 weeks after end of treatment
|
4 weeks and 24 weeks after the end of treatment, up to 64 weeks
|
|
Part 3 and 4: Plasma HCV RNA Level <25 IU/mL at Week 4 and 12 of Treatment
Zeitfenster: Week 4 and 12
|
Part 3 and 4: Plasma Hepatitis C Virus Ribonucleic acid (HCV RNA) level <25 IU/mL at week 4 and 12 of treatment
|
Week 4 and 12
|
|
Part 3 and 4: Sustained Virological Response (SVR) at 4 Weeks After End of Treatment
Zeitfenster: up to 28 weeks
|
Part 3 and 4: Sustained virological response (SVR) at 4 weeks after end of treatment
|
up to 28 weeks
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Allgemeine Veröffentlichungen
- Zeuzem S, Mantry P, Soriano V, Buynak RJ, Dufour JF, Pockros PJ, Wright D, Angus P, Buti M, Stern JO, Kadus W, Vinisko R, Bocher W, Mensa FJ. Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study. Eur J Gastroenterol Hepatol. 2016 Aug;28(8):923-6. doi: 10.1097/MEG.0000000000000649.
- Asselah T, Zeuzem S, Soriano V, Bronowicki JP, Lohse AW, Mullhaupt B, Schuchmann M, Bourliere M, Buti M, Roberts SK, Gane EJ, Stern JO, Voss F, Baum P, Gallivan JP, Bocher WO, Mensa FJ. ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection. PLoS One. 2015 Dec 9;10(12):e0144004. doi: 10.1371/journal.pone.0144004. eCollection 2015.
- Zeuzem S, Soriano V, Asselah T, Gane EJ, Bronowicki JP, Angus P, Lohse AW, Stickel F, Mullhaupt B, Roberts S, Schuchmann M, Manns M, Bourliere M, Buti M, Stern JO, Gallivan JP, Voss F, Sabo JP, Bocher W, Mensa FJ; SOUND-C2 Study Group. Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis. Antimicrob Agents Chemother. 2015 Feb;59(2):1282-91. doi: 10.1128/AAC.04383-14. Epub 2014 Dec 15.
- Zeuzem S, Soriano V, Asselah T, Bronowicki JP, Lohse AW, Mullhaupt B, Schuchmann M, Bourliere M, Buti M, Roberts SK, Gane EJ, Stern JO, Vinisko R, Kukolj G, Gallivan JP, Bocher WO, Mensa FJ. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med. 2013 Aug 15;369(7):630-9. doi: 10.1056/NEJMoa1213557.
- Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Mullhaupt B, Gane E, Schuchmann M, Lohse AW, Pol S, Bronowicki JP, Roberts S, Arasteh K, Zoulim F, Heim M, Stern JO, Nehmiz G, Kukolj G, Bocher WO, Mensa FJ. Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results. Antivir Ther. 2013;18(8):1015-9. doi: 10.3851/IMP2567. Epub 2013 Apr 4.
Nützliche Links
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn
1. Mai 2010
Primärer Abschluss (Tatsächlich)
1. Oktober 2014
Studienabschluss (Tatsächlich)
1. Oktober 2014
Studienanmeldedaten
Zuerst eingereicht
3. Mai 2010
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
26. Mai 2010
Zuerst gepostet (Schätzen)
28. Mai 2010
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
1. Februar 2016
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
22. Dezember 2015
Zuletzt verifiziert
1. Dezember 2015
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Verdauungssystems
- RNA-Virusinfektionen
- Viruserkrankungen
- Infektionen
- Durch Blut übertragene Infektionen
- Übertragbare Krankheiten
- Leberkrankheiten
- Flaviviridae-Infektionen
- Hepatitis, viral, menschlich
- Hepatitis, chronisch
- Hepatitis
- Hepatitis C
- Hepatitis C, chronisch
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Antivirale Mittel
- Antimetaboliten
- Ribavirin
Andere Studien-ID-Nummern
- 1241.21
- 2009-018197-66 (EudraCT-Nummer: EudraCT)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Hepatitis C, chronisch
-
Tripep ABInovio PharmaceuticalsUnbekanntChronische Hepatitis-C-VirusinfektionSchweden
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsZurückgezogenChronische Hepatitis-C-VirusinfektionIsrael
-
Hadassah Medical OrganizationUnbekanntChronische Hepatitis-C-VirusinfektionIsrael
-
Trek Therapeutics, PBCAbgeschlossenChronische Hepatitis C | Hepatitis-C-Genotyp 1 | Hepatitis C (HCV) | Hepatitis-C-VirusinfektionVereinigte Staaten, Neuseeland
-
Trek Therapeutics, PBCAbgeschlossenChronische Hepatitis C | Hepatitis C (HCV) | Hepatitis-C-Genotyp 4 | Hepatitis-C-VirusinfektionVereinigte Staaten
-
AbbVieAbgeschlossenHepatitis-C-Virus | Chronisches Hepatitis-C-Virus
-
ANRS, Emerging Infectious DiseasesUniversité Montpellier; Centre MurazAktiv, nicht rekrutierendChronische Hepatitis c | Hepatitis-C-Virusinfektion, Vergangenheit oder GegenwartBurkina Faso
-
AbbVieAbgeschlossenChronische Hepatitis C | Hepatitis C (HCV) | Hepatitis-C-Genotyp 1a
-
AbbVie (prior sponsor, Abbott)AbgeschlossenChronische Hepatitis C | Hepatitis-C-Genotyp 1 | Hepatitis C (HCV)Vereinigte Staaten, Australien, Kanada, Frankreich, Deutschland, Neuseeland, Puerto Rico, Spanien, Vereinigtes Königreich
-
Sohag UniversityRekrutierung
Klinische Studien zur BI 207127
-
Boehringer IngelheimAbgeschlossen
-
Boehringer IngelheimAbgeschlossen
-
Boehringer IngelheimBeendet
-
Boehringer IngelheimAbgeschlossen
-
Boehringer IngelheimAbgeschlossenHepatitis C, chronischFrankreich, Deutschland, Schweiz
-
Boehringer IngelheimAbgeschlossen
-
Boehringer IngelheimBeendet
-
Boehringer IngelheimAbgeschlossen
-
Boehringer IngelheimAbgeschlossen
-
Boehringer IngelheimAbgeschlossenHepatitis C, chronischVereinigte Staaten, Deutschland, Spanien, Vereinigtes Königreich